Develop Medicine: The GT20029 Gel Achieves Main Endpoint in Phase II Clinical Trial for Acne Treatment in China.

Landu Pharmaceuticals announced that the Phase II clinical trial of the self-developed novel androgen receptor-targeted protein degradation chimeric compound GT20029 for the treatment of acne in China has achieved top-line data. The data shows that the Phase II clinical trial has successfully met its primary endpoint, with results that are statistically significant and clinically meaningful. The compound has shown excellent efficacy, safety, and pharmacokinetic characteristics, and the recommended dose for the Phase III clinical trial has been determined to be 0.5%.